Stock listing
OTC:IDXG Interpace Biosciences, Inc. Stock
Follow Interpace Biosciences, Inc. into a list and get an email when it puts out news.
Share price · OTC:IDXG
$4.50 USD -0.93 (-17.1%)
Close on Nov 20, 2026
- Day range
- $4.44 – $4.60 USDNov 20, 2026
- Volume
- 2,800 sharesNov 20, 2026
- Market cap
- $26.56M USDAt the close on Nov 20, 2026 · price × 5.90M shares outstanding
- Traded on an average day
- $12,365 USDMedian day 700 shares · 10 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:IDXG · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.50 | -0.93 | -17.1% | $4.60 | $4.60 | $4.44 | 2,800 | |
| $5.43 | -0.57 | -9.5% | $5.40 | $5.45 | $5.40 | 1,760 | |
| $6.00 | -0.20 | -3.2% | $6.05 | $6.05 | $6.00 | 200 | |
| $6.20 | +0.15 | +2.5% | $6.20 | $6.20 | $6.20 | 327 | |
| $6.05 | -0.20 | -3.2% | $6.05 | $6.05 | $6.05 | 1 | |
| $6.25 | +0.05 | +0.8% | $6.20 | $6.25 | $6.20 | 600 | |
| $6.20 | 0.00 | 0.0% | $6.60 | $6.60 | $6.20 | 101 | |
| $6.20 | -0.80 | -11.4% | $6.20 | $6.20 | $6.20 | 5 | |
| $7.00 | 0.00 | 0.0% | $7.00 | $7.00 | $7.00 | 100 | |
| $7.00 | +1.28 | +22.4% | $5.74 | $7.00 | $5.74 | 1,207 | |
| $5.72 | +0.37 | +6.9% | $5.50 | $5.72 | $5.50 | 830 | |
| $5.35 | -0.37 | -6.5% | $5.35 | $5.35 | $5.35 | 1 | |
| $5.72 | +0.77 | +15.6% | $5.00 | $5.72 | $5.00 | 3,405 | |
| $4.95 | -0.55 | -10.0% | $5.45 | $5.45 | $4.95 | 1,500 | |
| $5.50 | -1.00 | -15.4% | $6.00 | $6.00 | $5.50 | 2,601 | |
| $6.50 | +1.10 | +20.4% | $5.80 | $6.50 | $5.80 | 2,750 | |
| $5.40 | +0.35 | +6.9% | $5.40 | $5.40 | $5.40 | 100 | |
| $5.05 | -0.05 | -1.0% | $5.05 | $5.25 | $5.05 | 522 | |
| $5.10 | +0.10 | +2.0% | $5.10 | $5.10 | $5.10 | 500 | |
| $5.00 | -0.15 | -2.9% | $5.09 | $5.29 | $5.00 | 2,917 | |
| $5.15 | -0.12 | -2.3% | $5.20 | $5.20 | $5.05 | 1,800 | |
| $5.27 | -0.248 | -4.5% | $5.38 | $5.39 | $5.27 | 3,300 | |
| $5.518 | -0.382 | -6.5% | $5.518 | $5.518 | $5.518 | 300 | |
| $5.90 | -0.23 | -3.8% | $6.073 | $6.13 | $5.90 | 3,700 | |
| $6.13 | +0.13 | +2.2% | $5.97 | $6.13 | $5.85 | 6,300 | |
| $6.00 | 0.00 | 0.0% | $6.00 | $6.00 | $6.00 | 400 | |
| $6.00 | 0.00 | 0.0% | $6.00 | $6.00 | $6.00 | 0 | |
| $6.00 | -0.025 | -0.4% | $6.32 | $6.32 | $6.00 | 400 | |
| $6.025 | 0.00 | 0.0% | $6.025 | $6.025 | $6.025 | 0 | |
| $6.025 | 0.00 | 0.0% | $6.025 | $6.025 | $6.025 | 0 | |
| $6.025 | -0.365 | -5.7% | $6.15 | $6.15 | $6.00 | 800 | |
| $6.39 | 0.00 | 0.0% | $6.39 | $6.39 | $6.39 | 0 | |
| $6.39 | -0.03 | -0.5% | $6.39 | $6.39 | $6.39 | 100 | |
| $6.42 | 0.00 | 0.0% | $6.42 | $6.42 | $6.42 | 0 | |
| $6.42 | +0.01 | +0.2% | $6.42 | $6.42 | $6.42 | 300 | |
| $6.41 | -0.06 | -0.9% | $6.25 | $6.425 | $6.01 | 4,700 | |
| $6.47 | 0.00 | 0.0% | $6.47 | $6.47 | $6.47 | 0 | |
| $6.47 | 0.00 | 0.0% | $6.47 | $6.47 | $6.47 | 0 | |
| $6.47 | +0.02 | +0.3% | $6.55 | $6.55 | $6.45 | 1,500 | |
| $6.45 | 0.00 | 0.0% | $6.45 | $6.45 | $6.45 | 0 | |
| $6.45 | 0.00 | 0.0% | $6.65 | $6.65 | $6.45 | 700 | |
| $6.45 | 0.00 | 0.0% | $6.45 | $6.45 | $6.45 | 200 | |
| $6.45 | -0.05 | -0.8% | $6.53 | $6.53 | $6.45 | 500 | |
| $6.50 | +0.20 | +3.2% | $6.45 | $6.50 | $6.45 | 700 | |
| $6.30 | -0.20 | -3.1% | $6.45 | $6.45 | $5.973 | 5,900 | |
| $6.50 | -0.07 | -1.1% | $6.50 | $6.60 | $6.50 | 8,200 | |
| $6.57 | +0.07 | +1.1% | $6.55 | $6.57 | $6.55 | 2,800 | |
| $6.50 | -0.413 | -6.0% | $6.80 | $6.80 | $6.50 | 300 | |
| $6.913 | 0.00 | 0.0% | $6.913 | $6.913 | $6.913 | 0 | |
| $6.913 | +0.403 | +6.2% | $6.69 | $6.913 | $6.50 | 3,300 | |
| $6.51 | -0.47 | -6.7% | $6.92 | $6.98 | $6.45 | 9,500 | |
| $6.98 | -0.02 | -0.3% | $7.058 | $7.058 | $6.98 | 5,300 | |
| $7.00 | -0.57 | -7.5% | $7.47 | $7.47 | $6.80 | 23,800 | |
| $7.57 | -0.048 | -0.6% | $7.59 | $7.59 | $7.57 | 5,500 | |
| $7.618 | +7.328 | +2526.9% | $6.50 | $7.80 | $6.50 | 2,500 | |
| $0.29 | 0.00 | 0.0% | $0.29 | $0.29 | $0.29 | 0 | |
| $0.29 | +0.006 | +2.1% | $0.284 | $0.314 | $0.284 | 7,100 | |
| $0.284 | -0.002 | -0.7% | $0.282 | $0.29 | $0.262 | 6,500 | |
| $0.286 | -0.019 | -6.1% | $0.288 | $0.29 | $0.285 | 2,000 | |
| $0.305 | -0.017 | -5.4% | $0.302 | $0.309 | $0.282 | 9,800 | |
| $0.322 | +0.008 | +2.5% | $0.316 | $0.326 | $0.316 | 29,800 |
Splits
2 splits since 2016 · OTC:IDXG · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- OTC:IDXG
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results
Latest news
Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results
Nov 16, 2026
Closed $6.00 (-3.2%) on Nov 17, 2026
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
Oct 14, 2026
Closed $5.27 (-4.5%) on Oct 15, 2026
Interpace Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 2 in the last 12 months · 2 in all · newest Nov 16, 2026 · oldest 2026
Valuation
P/E 1.2× against a median of 20.0×: the lowest of 3 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $23.63M USD
- P/E
- 1.2×
- EV/sales
- 0.6×
- EV/EBITDA
- 21.0×
- Price/book
- 1.1×
- Gross margin
- 65.6%
- Operating margin
- 1.7%
- Net margin
- 58.1%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- -0.33
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Interpace Biosciences, Inc. · OTC:IDXG | US$26.56M | US$23.63M | 1.2× | 0.6× | 21.0× | 1.1× | 58.1% | 0.0× | -0.33 |
| Abingdon Health PLC · LSE:ABDX | US$28.10M | US$26.11M | n/a | 1.8× | n/a | 3.5× | −19.4% | 0.2× | n/a |
| MedMira Inc. · TSXV:MIR | US$26.91M | US$27.23M | n/a | 105× | n/a | n/a | −808.2% | n/a | 0.29 |
| BIOQUAL, Inc. · OTC:BIOQ | US$26.83M | US$42.28M | n/a | 1.1× | n/a | 0.8× | −11.0% | 1.0× | -0.01 |
| Ikonisys SA · EURONEXT:ALIKO | US$26.75M | US$31.11M | n/a | 20.4× | n/a | 1.3× | −302.8% | 0.3× | n/a |
| Microbix Biosystems Inc. · TSX:MBX | US$26.27M | US$25.96M | n/a | 2.4× | n/a | 1.6× | −31.7% | 0.3× | 0.03 |
| Bioptic Inc. · TPEX:6850 | US$26.10M | US$22.55M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | n/a |
| genOway SA · EURONEXT:ALGEN | US$25.86M | US$38.95M | 25.4× | 1.7× | 8.7× | 1.1× | 4.4% | 0.7× | n/a |
| Orientbio, Inc. · KRX:002630 | US$25.17M | −US$3.29M | 14.6× | −0.1× | −0.8× | 0.5× | 8.1% | 0.0× | n/a |
| Genesystem Co., Ltd. · KRX:363250 | US$24.68M | US$22.48M | n/a | 29.8× | n/a | 2.8× | n/a | 0.2× | n/a |
| Clever Culture Systems Limited · ASX:CC5 | US$24.56M | US$25.41M | n/a | 8.3× | n/a | 4.9× | −48.4% | 0.4× | n/a |
| Median of the others | US$26.18M | US$26.04M | 20.0× | 2.4× | 3.9× | 1.6× | −25.5% | 0.3× | 0.03 |
Team and board
Officers
| Officer | Role |
|---|---|
| Thomas Burnell | President, CEO, Chairman of the Board |
| Christopher McCarthy | Chief Financial Officer and Chief Operating Officer |
| Interpace Biosciences | Investor Relations |
| Nicole Massoll | Chief Medical Officer |
| Syd Finkelstein | Chief Pathology Officer |
Board
| Director | Role |
|---|---|
| Thomas Burnell | President, CEO, Chairman of the Board |
| Joseph Keegan | Director |
| Ron Rocca | Director |
| Stephen J. Sullivan | Director |
| Vijay Aggarwal | Director |
Events
| Quarter | Results |
|---|---|
| Q1 2026 | May 7, 2026 |
| Q4 2025 | Mar 5, 2026 |
| Q3 2025 | Nov 13, 2025 |
| Q2 2025 | Aug 7, 2025 |
| Q1 2025 | May 19, 2025 |
| Q4 2024 | Mar 31, 2025 |
| Q3 2024 | Nov 4, 2024 |
| Q2 2024 | Aug 2, 2024 |
| Q1 2024 | May 9, 2024 · After close |
| Q4 2023 | Mar 7, 2024 |
All 20 quarters
| Quarter | Results |
|---|---|
| Q3 2023 | Nov 8, 2023 · After close |
| Q2 2023 | Aug 9, 2023 · After close |
| Q1 2023 | May 12, 2023 · After close |
| Q4 2022 | Mar 27, 2023 · After close |
| Q3 2022 | Nov 14, 2022 · After close |
| Q2 2022 | Aug 15, 2022 · After close |
| Q1 2022 | May 16, 2022 · After close |
| Q4 2021 | Mar 31, 2022 · After close |
| Quarter to Sep 30, 2021 | Nov 10, 2021 · After close |
| Quarter to Jun 30, 2021 | Aug 10, 2021 · After close |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.7M | 46.9M | 40.0M | 5.68M | 8.20M | 32.4M | 24.2M | 21.9M | 15.9M | 13.1M |
| Cost of revenue | 14.6M | 17.0M | 15.0M | 13.6M | 14.3M | 21.7M | 15.9M | 10.2M | 7.36M | 6.64M |
| Gross profit | 24.1M | 29.9M | 25.1M | 18.2M | 18.8M | 10.7M | 8.33M | 11.7M | 8.54M | 6.44M |
| Research and development | 642.0K | 676.0K | 636.0K | 703.0K | 1.49M | 2.79M | 2.81M | 2.12M | 1.46M | 1.65M |
| Operating income | 4.08M | 8.11M | 3.96M | -3.62M | -6.34M | -26.1M | -26.4M | -12.6M | -6.29M | -6.44M |
| Depreciation and amortization | 425.0K | 300.0K | 1.03M | 2.56M | 5.37M | 5.50M | 4.52M | 3.80M | 3.69M | 4.48M |
| EBITDA | 4.51M | 8.41M | 4.98M | -1.06M | -962.0K | -20.6M | -21.9M | -8.83M | -2.60M | -1.96M |
| Interest expense | 549.0K | 440.0K | 331.0K | 433.0K | 2.14M | |||||
| Income before tax | 3.77M | 6.95M | 2.28M | -5.84M | -7.74M | -26.1M | -26.7M | -12.7M | -13.1M | -8.57M |
| Income tax | -21.2M | 4.00K | 17.0K | 29.0K | -705.0K | 53.0K | -28.0K | 18.0K | -395.0K | -162.0K |
| Net income | 24.6M | 6.70M | 1.95M | -22.0M | -14.9M | -26.5M | -26.7M | -12.7M | 12.6M | -22.0M |
| Earnings per share, basic | 5.55 | 1.42 | 0.45 | -5.18 | -3.61 | -7.32 | -7.25 | -4.52 | -7.96 | -120.90 |
| Earnings per share, diluted | 0.89 | 0.40 | 0.45 | -5.18 | -3.61 | -7.32 | -7.25 | -4.52 | -7.96 | -120.90 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.50M | 1.46M | 3.50M | 4.83M | 2.67M | 2.77M | 2.32M | 6.07M | 15.2M | 602.0K |
| Receivables | 5.65M | 8.54M | 5.08M | 5.03M | 4.67M | 8.03M | 10.3M | 9.48M | 3.44M | 2.21M |
| Inventory | 1.11M | 1.21M | 1.23M | 1.22M | 825.0K | 2.05M | 1.82M | |||
| Current assets | 9.90M | 11.8M | 10.4M | 12.2M | 12.2M | 14.1M | 16.5M | 17.7M | 19.8M | 4.24M |
| Property, plant and equipment | 1.42M | 1.36M | 790.0K | 480.0K | 317.0K | 7.35M | 6.81M | 837.0K | 654.0K | 929.0K |
| Goodwill | 8.43M | 8.43M | 8.43M | |||||||
| Total assets | 33.8M | 14.8M | 13.1M | 16.0M | 38.4M | 45.7M | 51.5M | 31.1M | 36.6M | 25.1M |
| Accounts payable | 983.0K | 1.66M | 1.54M | 1.05M | 1.37M | 4.51M | 4.71M | 1.06M | 391.0K | 2.33M |
| Current liabilities | 5.10M | 10.6M | 11.4M | 14.3M | 15.7M | 18.2M | 17.3M | 8.67M | 8.09M | 16.2M |
| Long-term debt | 1.85M | 520.0K | 3.68M | 2.71M | 7.91M | |||||
| Total debt | 578.0K | 762.0K | 1.20M | 1.50M | 7.91M | |||||
| Total liabilities | 11.5M | 17.0M | 22.1M | 32.5M | 34.3M | 28.2M | 29.8M | 15.7M | 13.7M | 35.2M |
| Shareholders' equity | 22.4M | -2.22M | -55.5M | -58.1M | -42.4M | -29.1M | -4.48M | 15.4M | 22.9M | -10.1M |
| Shares outstanding | 885.7K | 4.41M | 4.35M | 4.30M | 4.20M | 4.06M | 3.92M | 2.87M | 27.8M | 2.18M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 5.83M | 4.65M | 3.79M | -7.69M | -8.72M | -14.0M | -19.0M | -8.67M | -15.3M | -7.61M |
| Capital spending | -356.0K | -876.0K | -470.0K | -322.0K | -354.0K | -1.57M | -131.0K | -449.0K | -29.0K | |
| Free cash flow | 5.47M | 3.77M | 3.32M | -8.01M | -9.07M | -15.6M | -19.1M | -9.12M | -15.3M | |
| Cash from investing | -356.0K | -876.0K | -87.0K | 6.21M | -315.0K | -1.57M | -13.9M | -449.0K | -29.0K | |
| Cash from financing | -4.43M | -5.81M | -5.03M | 3.00M | 8.98M | 16.6M | 29.2M | -9.00K | 29.9M | -101.0K |
| Change in cash | 1.04M | -2.04M | -1.33M | 1.51M | -58.0K | 1.05M | -3.75M | -9.13M | 14.6M | -7.71M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| RW · Request to withdraw a registration | Nov 18, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 17, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| CERT · Exchange's certificate of listing | Nov 5, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Nov 5, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Oct 30, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Oct 15, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 15, 2026 | Results | SEC |
| S-1/A · Registration statement, amended | Sep 30, 2026 | Offer document | SEC |
| S-1 · Registration statement | Sep 24, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 · Registration statement for employee plans | Sep 17, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 27, 2026 | Current report | SEC |
| 8-K/A · Current report, amended | Aug 26, 2026 | Management or board change | SEC |
| 8-K · Current report | Aug 20, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| DRS · Draft registration statement | Jul 22, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Jul 7, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 7, 2026 | Meeting notice | SEC |
| PREM14A | Jun 24, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Jun 23, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| 8-K · Current report | Apr 1, 2026 | Results | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 20, 2026 | Results | SEC |
| 8-K · Current report | Dec 3, 2025 | Current report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 8-K · Current report | Apr 30, 2025 | Current report | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2025 | Annual report | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 27, 2025 | Current report | SEC |
| 8-K · Current report | Jan 21, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 8-K · Current report | Nov 13, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 16, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 16, 2024 | Big-stake notice | SEC |
| D | Oct 16, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 15, 2024 | Material contract | SEC |
| DEFA14A · Additional proxy material | Sep 20, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 20, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 2, 2024 | Results | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 26, 2024 | Annual report | SEC |
| 10-K · Annual report | Apr 1, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 16, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 27, 2023 | Material contract | SEC |
| DEFA14A · Additional proxy material | Sep 22, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 22, 2023 | Meeting notice | SEC |
| 8-K · Current report | Aug 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Aug 1, 2023 | Insider trade | SEC |
| 8-K · Current report | May 12, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| 3 · Initial statement of ownership | May 3, 2023 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2023 | Annual report | SEC |
| 8-K · Current report | Apr 24, 2023 | Management or board change | SEC |
| 8-K · Current report | Mar 27, 2023 | Results | SEC |
| 10-K · Annual report | Mar 27, 2023 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 15, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
| 8-K · Current report | Nov 4, 2022 | Material contract | SEC |
| 8-K · Current report | Oct 4, 2022 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Sep 20, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 20, 2022 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 9, 2022 | Meeting notice | SEC |
| 8-K · Current report | Sep 7, 2022 | Acquisition or disposal | SEC |
| 8-K · Current report | Aug 15, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 15, 2022 | Quarterly report | SEC |
| RW · Request to withdraw a registration | Jun 16, 2022 | Other filings | SEC |
| 10-Q · Quarterly report | May 16, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 16, 2022 | Results | SEC |
| 8-K · Current report | May 10, 2022 | Material contract | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2022 | Annual report | SEC |
| 8-K · Current report | Apr 14, 2022 | Current report | SEC |
| 8-K · Current report | Mar 31, 2022 | Results | SEC |
| 10-K · Annual report | Mar 31, 2022 | Annual report | SEC |
| SC 13G · Big-stake notice | Feb 10, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 2, 2022 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 1, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Jan 28, 2022 | Current report | SEC |
| 8-K · Current report | Jan 27, 2022 | Material contract | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 13, 2022 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jan 13, 2022 | Other filings | SEC |
| 424B4 · Prospectus | Jan 12, 2022 | Offer document | SEC |
| POS EX | Jan 12, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 10, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 7, 2022 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jan 3, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 10, 2021 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 6, 2021 | Big-stake notice | SEC |
| S-1 · Registration statement | Dec 3, 2021 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 12, 2021 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 12, 2021 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2021 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2021 | Results | SEC |
| 8-K · Current report | Nov 9, 2021 | Meeting outcome | SEC |
| 8-K · Current report | Nov 2, 2021 | Material contract | SEC |
| 8-K · Current report | Oct 18, 2021 | Material contract | SEC |
| 8-K · Current report | Oct 1, 2021 | Material contract | SEC |
| DEF 14A · Proxy statement | Sep 27, 2021 | Meeting notice | SEC |
| 8-K · Current report | Aug 31, 2021 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Aug 27, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 20, 2021 | Other filings | SEC |
| 10-K/A · Annual report, amended | Aug 20, 2021 | Annual report | SEC |
| 10-K/A · Annual report, amended | Aug 20, 2021 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Aug 11, 2021 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 10, 2021 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2021 | Results | SEC |
| 8-K · Current report | Aug 6, 2021 | Current report | SEC |
| 8-K · Current report | Jun 29, 2021 | Material contract | SEC |
| 4 · Change in ownership | May 25, 2021 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | May 19, 2021 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | May 18, 2021 | Big-stake notice | SEC |
| 8-K · Current report | May 11, 2021 | Results | SEC |
| 10-Q · Quarterly report | May 11, 2021 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2021 | Annual report | SEC |
| 25-NSE | Apr 26, 2021 | Other filings | SEC |
| 8-K · Current report | Apr 5, 2021 | Results | SEC |
| 10-K · Annual report | Apr 1, 2021 | Annual report | SEC |
| NT 10-K · Late filing notice | Apr 1, 2021 | Explanation request | SEC |
| 4 · Change in ownership | Mar 12, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 1, 2021 | Insider trade | SEC |
| SC 13D · Big-stake notice | Mar 1, 2021 | Big-stake notice | SEC |
| 8-K · Current report | Feb 24, 2021 | Current report | SEC |
| 8-K · Current report | Feb 17, 2021 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2021 | Big-stake notice | SEC |
| 8-K · Current report | Feb 4, 2021 | Management or board change | SEC |
| 4 · Change in ownership | Feb 2, 2021 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 29, 2021 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 21, 2021 | Big-stake notice | SEC |
| 8-K · Current report | Jan 20, 2021 | Results | SEC |
| 10-Q · Quarterly report | Jan 19, 2021 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Jan 19, 2021 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Jan 19, 2021 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jan 19, 2021 | Annual report | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 19, 2021 | Big-stake notice | SEC |
| 8-K · Current report | Jan 11, 2021 | Material contract | SEC |
| 8-K · Current report | Dec 7, 2020 | Current report | SEC |
| 4 · Change in ownership | Dec 2, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2020 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 2, 2020 | Insider trade | SEC |
| 8-K · Current report | Nov 25, 2020 | Management or board change | SEC |
| 8-K · Current report | Nov 19, 2020 | Current report | SEC |
| NT 10-Q · Late filing notice | Nov 17, 2020 | Explanation request | SEC |
| 8-K · Current report | Oct 23, 2020 | Material contract | SEC |
| 8-K · Current report | Oct 20, 2020 | Results | SEC |
| 10-Q · Quarterly report | Oct 19, 2020 | Quarterly report | SEC |
| 8-K · Current report | Oct 14, 2020 | Current report | SEC |
| SC 13G · Big-stake notice | Sep 11, 2020 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 20, 2020 | Big-stake notice | SEC |
| 8-K · Current report | Aug 20, 2020 | Current report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2020 | Explanation request | SEC |
| 8-K · Current report | Aug 14, 2020 | Current report | SEC |
| 4 · Change in ownership | Jul 31, 2020 | Insider trade | SEC |
| SC 13D · Big-stake notice | Jul 24, 2020 | Big-stake notice | SEC |
| 8-K · Current report | Jul 14, 2020 | Management or board change | SEC |
| 4 · Change in ownership | Jul 13, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2020 | Insider trade | SEC |
| 10-Q · Quarterly report | Jun 26, 2020 | Quarterly report | SEC |
| 8-K · Current report | Jun 25, 2020 | Results | SEC |
| DEF 14A · Proxy statement | Jun 9, 2020 | Meeting notice | SEC |
| 8-K · Current report | Jun 9, 2020 | Material contract | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Interpace Biosciences, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 5,901,964
- Fully diluted
- 5,901,964
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 5,901,964 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 5,901,964 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jack E Stover Other companies: TransCode Therapeutics, Inc. (Director · Since at least Dec 19, 2025); Profusa, Inc. (Chief Executive Officer · Since at least Dec 20, 2021); Traws Pharma, Inc. (Director · Since at least May 18, 2016); PharmaCyte Biotech, Inc. (Director · Aug 15, 2022 – Aug 15, 2022 · Past); Antares Pharma Inc (President and CEO, Director · Jan 25, 2006 – May 14, 2008 · Past) | President and CEO, Director · Aug 3, 2005 – Mar 12, 2020 · Past |
| Graham G Miao Other companies: AgroFresh Solutions Inc (Chief Financial Officer · Aug 30, 2018 – Mar 31, 2023 · Past); Pernix Therapeutics Holdings Inc (President and CFO, Director · Jul 26, 2016 – Aug 8, 2017 · Past); Delcath Systems, Inc. (Interim Co-CEO & Pres.EVP, CFO · Sep 26, 2011 – Nov 14, 2013 · Past) | CFO · Oct 20, 2014 – Dec 28, 2015 · Past |
| Joseph D. Keegan Other companies: Bio-Techne Corp (Director · Since at least Oct 26, 2017); Stereotaxis, Inc. (Director · Feb 16, 2011 – May 24, 2016 · Past) | Director · Since at least Jan 1, 2016 |
| Veronica Lubatkin Other companies: Par Pharmaceutical Companies Inc (EVP, Chief Financial Officer · Jun 5, 2007 – Dec 31, 2008 · Past) | Director · Nov 18, 2008 – Jun 4, 2013 · Past |
| Christopher McCarthy | Chief Financial Officer and Chief Operating Officer · Since at least Apr 21, 2023 |
| Edward Chan | Director · Jan 15, 2020 – Jan 15, 2020 · Past |
| Eric B Lev | Director · Jul 15, 2019 – Jan 15, 2020 · Past |
| Felice Schnoll-Sussman | Director · Sep 12, 2017 – Mar 7, 2018 · Past |
| Gerald P Belle | Director · Jun 4, 2013 – Jun 3, 2015 · Past |
| Gregory Richard | Chief Commerical Officer · Sep 14, 2017 – Jan 22, 2020 · Past |
All 22 people
| Person | Seat |
|---|---|
| Howard Drazner | SVP,Bus. Dev Medical Education · Apr 1, 2009 – Nov 29, 2010 · Past |
| Interpace Biosciences | Investor Relations · Since at least Oct 15, 2026 |
| Jeffrey Edward Smith | VP of Corporate Development · Jan 30, 2012 – Nov 7, 2014 · Past |
| Jo Ann Saitta | SVP and CIO, GM GROUP DCA · Jan 31, 2012 – Mar 1, 2013 · Past |
| Joseph I Curti | Director · Jun 6, 2006 – Jun 4, 2009 · Past |
| Nicole Massoll | Chief Medical Officer · Since at least Nov 5, 2026 |
| Ron Rocca | Director · Since at least Nov 4, 2026 |
| Stephen Cotugno | Executive Vice-President · Feb 15, 2006 – Feb 15, 2006 · Past |
| Stephen J. Sullivan | Director · Since at least Jul 9, 2020 |
| Syd Finkelstein | Chief Pathology Officer · Since at least Nov 5, 2026 |
| Thomas Burnell | President, CEO, Chairman of the Board · Since at least Nov 5, 2026 |
| Vijay Aggarwal | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Interpace Biosciences, Inc.